GlycoMimetics Incorporated
Crescent Biopharma is a leading oncology company dedicated to developing next-generation therapies for cancer patients. With a focus on solid tumors, the company leverages multiple modalities and established targets to create potentially best-in-class therapeutics. Originating from Paragon Therapeutics, Crescent aims to rapidly advance transformative therapies through innovative biologics and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Products
CR-001
Tetravalent PD-1 x VEGF bispecific antibody candidate designed for treatment of solid tumors, with structural design intended to localize activity to the tumor microenvironment; planned IND submission and Phase 1 study.
CR-002
Antibody-drug conjugate candidate designed to deliver topoisomerase inhibitor payloads to tumor cells; intended for monotherapy and combination with bispecific immunotherapy. Target identity to be disclosed as program advances.
CR-003
Antibody-drug conjugate candidate designed to deliver topoisomerase inhibitor payloads to tumor cells with potential for monotherapy and combination regimens with bispecific immunotherapies.
CR-001
Tetravalent PD-1 x VEGF bispecific antibody candidate designed for treatment of solid tumors, with structural design intended to localize activity to the tumor microenvironment; planned IND submission and Phase 1 study.
CR-002
Antibody-drug conjugate candidate designed to deliver topoisomerase inhibitor payloads to tumor cells; intended for monotherapy and combination with bispecific immunotherapy. Target identity to be disclosed as program advances.
CR-003
Antibody-drug conjugate candidate designed to deliver topoisomerase inhibitor payloads to tumor cells with potential for monotherapy and combination regimens with bispecific immunotherapies.
Expertise Areas
- Oncology therapeutic development
- Bispecific antibody therapeutics
- Antibody-drug conjugate (ADC) development
- Immuno-oncology
Key Technologies
- Bispecific antibody engineering
- Tetravalent antibody formats
- Antibody-drug conjugates (ADCs)
- Topoisomerase inhibitor payloads